Subjects were recruited from DAISY, which is an ongoing prospective birth cohort study following genetically at-risk individuals for development of islet Aabs and clinical T1D (32). Written informed consent was obtained from each participant and guardian when the participant was less than 18 y of age, and the Colorado Multiple Institutional Review Board approved the study. Study visits occurred every 6 to 12 mo to collect peripheral blood for islet Aab measurements and ELISPOT assays. Additionally, glucose measurements were performed in the Aab+ cohort.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.